Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Ching-Yi Kuan

Ching-Yi Kuan

National Pingtung University of Science and Technology, Taiwan

Title: Study on the inhibitory activity of 3'-hydroxypterostilbene on tumor growth in xenograft model of human prostate cancer cells

Biography

Biography: Ching-Yi Kuan

Abstract

According to the Ministry of Health and Welfare in Taiwan, prostate cancer is the sixth highest cause of cancer-related   death. Besides, prostate cancer cells will metastasize to bones and lymph nodes, so it’s important that prevention and treatment of prostate cancer. In this study, 3'-hydroxypterostilbene (OHPt), a structural analogue of pterostilbene (Pt), were used as experimental samples to investigate the potent anti-tumor effects in PC-3 xenografted nude mice. 1×106 PC-3 cells were injected subcutaneously into the flanks of 30 male Balb/c nude mice to form tumors. When xenografted tumor volume reached around 100 mm3, mice were randomly divided into five groups. Each group consisted of 6 animals. Mice were orally administrated with daily doses of OHPt (5, 25 and 50 mg/kg/d) and Pt (25 mg/kg/d) for 4 weeks; while control group was orally administrated with olive oil only. During the experiment, the tumor volume was determined and recorded once or twice per week using caliper measurements. At the end of the experiment, animals were sacrificed by CO2 asphyxiation and the individual tumors were excised immediately and weighed. Further the protein expression of tumors was measured. The results showed that the treatment of mice with OHPt could inhibit the tumor volume and tumor weight in a dose-dependent manner, and increased the expression of c-caspase-3 while decreased the expression of MMP-9 and Cox-2. In conclusion, these results revealed that OHPt might be a potential agent to treat prostate cancer.